Method for Reducing or Preventing Immunogenic Response

Case ID: 00985


This invention involves the use of humanized cobra venom factor (hCVF) to prevent or reduce immunogenicity and other unwanted immunological reactions as a consequence of administering biologics therapy. In many therapeutic situations, biologics agents may induce unwanted immune response that can cause clinical challenges and ineffective treatment. hCVF depletes complement, an integral component of both innate and adaptive immunity, so hCVF is administered to deplete complement levels and reduce or prevent immune response to a biological therapeutic agent.



  • Use of humanized cobra venom factor to reduce or prevent an immune response to biologics therapies.
  • Potential treatment targets - blood clotting disorder, hemophilia A, rheumatoid arthritis, age-related macular degeneration, paroxysmal nocturnal hemoglobjnuria, Myasthenia gravis, Crohn's disease, myocardial ischemia, reperfusion, cardiopulmonary bypass, transplantation, myocardial infarction, angioplasty.



Humanized cobra venom factor has been made and tested in vitro in different disease models.

Patent Information:
Carl-Wilhelm Vogel
Paul Finnegan
Julie Rayes
Sebastien Lacroix-Desmazes

For information, contact:
Ann Park
Technology Licensing Associate
University of Hawaii
(808) 956-9929

© 2019. All Rights Reserved. Powered by Inteum